Trypsin activation pathway of rotavirus infectivity.
The infectivity of rotaviruses is increased by and most probably is dependent on trypsin treatment of the virus. This proteolytic treatment specifically cleaves VP4, the protein that forms the spikes on the surface of the virions, to polypeptides VP5 and VP8. This cleavage has been reported to occur in rotavirus SA114fM at two conserved, closely spaced arginine residues located at VP4 amino acids 241 and 247. In this work, we have characterized the VP4 cleavage products of rotavirus SA114S generated by in vitro treatment of the virus with increasing concentrations of trypsin and with proteases AspN and alpha-chymotrypsin. The VP8 and VP5 polypeptides were analyzed by gel electrophoresis and by Western blotting (immunoblotting) with antibodies raised to synthetic peptides that mimic the terminal regions of VP4 generated by the trypsin cleavage. It was shown that in addition to arginine residues 241 and 247, VP4 is cleaved at arginine residue 231. These three sites were found to have different susceptibilities to trypsin, Arg-241 > Arg-231 > Arg-247, with the enhancement of infectivity correlating with cleavage at Arg-247 rather than at Arg-231 or Arg-241. Proteases AspN and alpha-chymotrypsin cleaved VP4 at Asp-242 and Tyr-246, respectively, with no significant enhancement of infectivity, although this enhancement could be achieved by further treatment of the virus with trypsin. The VP4 end products of trypsin treatment were a homogeneous VP8 polypeptide comprising VP4 amino acids 1 to 231 and a heterogeneous VP5, which is formed by two polypeptide species (present at a ratio of approximately 1:5) as a result of cleavage at either Arg-241 or Arg-247. A pathway for the trypsin activation of rotavirus infectivity is proposed.
Arias
C F
CF
Departamento de Genética y Fisiología Molecular, Universidad Nacional Autónoma de México, Cuernavaca, Morelos, Mexico. arias@ibt.unam.mx
Romero
P
P
Alvarez
V
V
López
S
S
D000595:Amino Acid Sequence; D000818:Animals; D000906:Antibodies; D001120:Arginine; D015153:Blotting, Western; D002213:Capsid / Q000032:analysis / Q000096:biosynthesis*; D036022:Capsid Proteins; D002417:Cattle; D002460:Cell Line; D002918:Chymotrypsin / Q000378:metabolism; D010450:Endopeptidases / Q000378:metabolism; D006801:Humans; D008715:Methionine / Q000378:metabolism; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000737:chemistry / Q000276:immunology; D012401:Rotavirus / Q000187:drug effects / Q000472:pathogenicity* / Q000502:physiology*; D013379:Substrate Specificity; D014357:Trypsin / Q000378:metabolism / Q000494:pharmacology*; D014771:Virion / Q000187:drug effects / Q000502:physiology
D000906:Antibodies; D036022:Capsid Proteins; D010446:Peptide Fragments; C060339:VP4 protein, Rotavirus; D001120:Arginine; D008715:Methionine; D010450:Endopeptidases; D002918:Chymotrypsin; D014357:Trypsin